deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT05620134

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable Locally Advanced or Metastatic Cancer

Sponsor: Salubris Biotherapeutics Inc

Conditions Advanced Solid Tumor Cancer Clear Cell Renal Cell Carcinoma Colorectal Adenocarcinoma Colorectal Cancer Epithelial Ovarian Cancer Gastric Adenocarcinoma GastroEsophageal Cancer Hepatocellular Carcinoma Luminal Breast Cancer Melanoma Metastatic Cancer Non-small Cell Lung Cancer Pancreatic Adenocarcinoma Papillary Renal Cell Carcinoma Small-cell Lung Cancer Squamous Cell Carcinoma Skin Squamous Cell Carcinoma of Head and Neck Thyroid Cancer Triple Negative Breast Cancer Tumor, Solid Urothelial Carcinoma
Interventions JK08 Lenvatinib Pill Pembrolizumab
Updated 8 times since 2022 Last updated: Oct 11, 2024 Started: Oct 17, 2022 Primary completion: Oct 17, 2025 Completion: Feb 20, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Advanced Solid Tumor and Cancer and is currently ongoing. Salubris Biotherapeutics Inc leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshotRecruiting~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshotRecruiting~Mar 2023 – ~May 2024 · 14 months · monthly snapshotRecruiting~May 2024 – ~Jul 2024 · 2 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshotRecruiting~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshotRecruiting~Nov 2024 – present · 21 months · monthly snapshotActive Not Recruiting

Change History

8 versions recorded

  1. Nov 2024 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Oct 2024 — Nov 2024 [monthly]

    Recruiting PHASE1/PHASE2

  3. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 3 earlier versions

  1. Mar 2023 — May 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Oct 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Salubris Biotherapeutics Inc
Data source: Salubris Biotherapeutics Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations